{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444408658
| ImageFile=Ibacitabine.svg
| IUPACName=4-amino-1-[(2''R'',4''S'',5''R'')-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one
| OtherNames=
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3EK8532DZV
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=611-53-0
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2104340
| PubChem=65050
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07200
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 58561
| SMILES = OCC1[C@@H](O)C[C@@H](O1)N2C=C(I)C(N)=NC2=O
| InChI = 1/C9H12IN3O4/c10-4-2-13(9(16)12-8(4)11)7-1-5(15)6(3-14)17-7/h2,5-7,14-15H,1,3H2,(H2,11,12,16)/t5-,6+,7+/m0/s1
| InChIKey = WEVJJMPVVFNAHZ-RRKCRQDMBC
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C9H12IN3O4/c10-4-2-13(9(16)12-8(4)11)7-1-5(15)6(3-14)17-7/h2,5-7,14-15H,1,3H2,(H2,11,12,16)/t5-,6+,7+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = WEVJJMPVVFNAHZ-RRKCRQDMSA-N
  }}
|Section2={{Chembox Properties
| Formula=C<sub>9</sub>H<sub>12</sub>IN<sub>3</sub>O<sub>4</sub>
| MolarMass=353.11375
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
  }}
|Section6={{Chembox Pharmacology
| ATCCode_prefix = D06
| ATCCode_suffix = BB08
}}
|Section7={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
  }}
}}
'''Ibacitabine''' (or '''ibacitabin''',<ref>{{cite journal | pmid = 10739980 | volume=127 | issue=2 | title=[Contact dermatitis to topical antiviral drugs] |date=February 2000 | journal=Ann Dermatol Venereol | pages=191â€“3}}</ref> or '''5-iodo-2'-deoxy[[cytidine]] ''') is an [[antiviral drug]].

==References==
{{reflist}}

==External links==
* {{ATC|D06|BB08}}
{{Antibiotics and chemotherapeutics for dermatological use}}






{{dermatologic-drug-stub}}

[[Category:Antivirals]]
[[Category:Pyrimidones]]
[[Category:Organoiodides]]